Immediate intravesical chemotherapy for low-grade bladder tumors in California: An underutilized practice and its impact on recurrence

The delivery of quality care in cancer in the United States has been described as being in a state of crisis [1], while the cost of health care continues to grow to unsustainable levels [2]. Furthermore, the burden of bladder cancer in the United States is significant, with over 79,030 new cases estimated in 2017, and it remains the most prevalent malignancy of the urinary system with an estimated prevalence in the United States of 696,440 in 2014 [3]. The majority of incident cases represent nonmuscle invasive and low-grade disease.

Source: Urologic Oncology: Seminars and Original Investigations - September 17, 2018 Category: Urology & Nephrology Authors: Stanley A. Yap, Ann Brunson, Neil Pugashetti, Rosemary D. Cress, M.P.H., Theresa H.M. Keegan, Ralph deVere White, Ted Wun Tags: Original article Source Type: research